Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avenue Therapeutics Inc (ATXI)
NASDAQ:ATXI
RESEARCH TOOLSreports
Holding ATXI?
Track your performance easily
ATXI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.25 - $57.75
Previous Close$2.7
Volume5.09K
Average Volume (3M)46.56K
Market Cap
$3.81M
Enterprise Value-$1.99M
Total Cash (Recent Filing)$4.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.57
Next Earnings
Nov 06, 2024EPS Estimate
-$0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.41
Shares Outstanding1,431,356
10 Day Avg. Volume26,735
30 Day Avg. Volume46,560
Standard Deviation0.36
R-Squared0.00064
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.81
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$12.00Price Target Upside351.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Avenue Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPositive data from the AJ201 study could position Avenue Therapeutics to raise additional capital for advancing the program to later-stage development.
Market OpportunityPotential plans for BAER-101, which is P2a-ready for rare epilepsies, and IV Tramadol could attract potential partnerships.
Strategic FocusThe company's strategic pivot to focus on rare diseases by licensing AJ201 highlights its commitment to addressing unmet medical needs in the neurologic disease space.
Bears Say
Capital NeedsAvenue is exploring additional financing options, which may include potential partnerships.
Financial PerformanceAvenue reported a net loss of $2.7 million.
Stock ValuationThe price target has been significantly reduced to $12 from $56.25 due to capital needs and potential dilution.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATXI FAQ
What was Avenue Therapeutics Inc’s price range in the past 12 months?
Avenue Therapeutics Inc lowest stock price was $2.25 and its highest was $57.75 in the past 12 months.
What is Avenue Therapeutics Inc’s market cap?
Currently, no data Available
When is Avenue Therapeutics Inc’s upcoming earnings report date?
Avenue Therapeutics Inc’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Avenue Therapeutics Inc’s earnings last quarter?
Avenue Therapeutics Inc released its earnings results on Aug 09, 2024. The company reported -$6.43 earnings per share for the quarter, missing the consensus estimate of -$1.05 by -$5.38.
Is Avenue Therapeutics Inc overvalued?
According to Wall Street analysts Avenue Therapeutics Inc’s price is currently Undervalued.
Does Avenue Therapeutics Inc pay dividends?
Avenue Therapeutics Inc does not currently pay dividends.
What is Avenue Therapeutics Inc’s EPS estimate?
Avenue Therapeutics Inc’s EPS estimate is -$0.94.
How many shares outstanding does Avenue Therapeutics Inc have?
Avenue Therapeutics Inc has 1,431,356 shares outstanding.
What happened to Avenue Therapeutics Inc’s price movement after its last earnings report?
Avenue Therapeutics Inc reported an EPS of -$6.43 in its last earnings report, missing expectations of -$1.05. Following the earnings report the stock price went up 0.403%.
Which hedge fund is a major shareholder of Avenue Therapeutics Inc?
Currently, no hedge funds are holding shares in ATXI
---
Avenue Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (351.13% Upside)
$12.00 (351.13% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
199.40%
Trailing 12-Months
Company Description
Avenue Therapeutics Inc
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
---
ATXI Stock 12 Month Forecast
Average Price Target
$12.00
▲(351.13% Upside)
Technical Analysis
Best Analysts Covering ATXI
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-48.72%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -48.72% per trade.
---